Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
FerroKin BioSciences, Inc.
ClinicalTrials.gov Identifier:
NCT01039636
First received: December 23, 2009
Last updated: February 8, 2012
Last verified: January 2011
  Purpose

The purpose of this research study is to study the safety of increasing doses of FBS0701, and to see how quickly the study medication is absorbed and how quickly it disappears from the bloodstream. FBS0701 is a new, oral iron chelator - a medication taken by mouth that increases the body's elimination of iron. Iron chelators are used in patients who develop iron overload from their transfusions. Four increasing doses of FBS0701 will be tested during this study. The study will start with the lowest dose given to 4 patients (3 mg/kg/day. The next group of 4 patients will receive the next high dose (8mg/kg/day only after the results of the first 4 patients are examined and it is determined safe to continue. Participating patients will take the study medication for 7 days and be followed for 28 days after their last dose to determine if they have any reactions to the study medication - therefore a total of 35 days on study. Patients will need to give up to 17 blood samples over the screening period and first 15 days of the study (a total of about 9 tablespoons). Patients will not need to stay overnight in the clinic but will need to visit the clinic 10 times for screening and on-study visits over the 35 days. Patients currently taking an iron chelator will need to stop that treatment for up to 22 days (up to 5 days before they start the study and for 15 days during the study). The results of this study will be helpful in determining the safety of the drug and the best doses of FBS0701 to be used in the next study which will assess the effectiveness of this new iron chelator.


Condition Intervention Phase
Transfusional Iron Overload
Beta-thalassemia
Drug: FBS0701
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A PHASE 1b OPEN LABEL, MULTI-CENTER, ESCALATING MULTIPLE DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF FBS0701 IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD

Resource links provided by NLM:


Further study details as provided by FerroKin BioSciences, Inc.:

Primary Outcome Measures:
  • Safety and tolerability by AEs, Physical Exam, Clinical Laboratory assessments [ Time Frame: 35 days (7 days treatment and 28 days follow up) ] [ Designated as safety issue: Yes ]
  • Steady state plasma level and half-life of FBS0701 [ Time Frame: 7 days of dosing ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Urinary excretion of iron [ Time Frame: 7 days of dosing ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: November 2009
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FBS0701 - 5 escalating doses
5 escalating doses of FBS0701 in 5 cohorts of 4 patients each.
Drug: FBS0701
Oral FBS0701 for 7 days at one of the following doses: 3 mg/kg/day or 8 mg/kg/day or 16 mg/kg/day or 32 mg/kg/day or 40 mg/kg/day

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • At least 18 years old
  • Transfusion dependent (at least 8 transfusions per year) with transfusional iron overload needing treatment with deperoxamine, deferasirox or deperiprone.
  • Willing to discontinue current iron chelation therapy for 2-5 days prior to enrollment and for a total of up to 3 weeks
  • Willing to fast after midnight prior to each dose
  • Serum ferritin greater than 400ng/ml
  • Liver iron concentration greater than or equal to 1.5 mg iron. (determined by MRI or SQUID within 12 months prior to enrollment)
  • Cardiac iron greater than or equal to 12 milliseconds (determined by MRI t2* within 18 months prior to enrollment)
  • Mean of last 3 pre-transfusion hemoglobin values must be greater than or equal to 7.5 g/dl
  • Agrees to use approved contraception from Screening and until 30 days after last administration of study drug. Abstinence OK.

Exclusion Criteria:

  • Principal Investigator considers patient unfit for study after conducting a medical review, physical examination and other screening assessments.
  • Non-elective hospitalization with past 30 days
  • Evidence of clinically relevant oral, cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric or skin disorder.
  • Evidence of significant renal insufficiency; serum creatine above upper limit of normal or proteinuria greater than 2 gm per day or calculated creatinine clearance of less than or equal to 60ml/min
  • Platelet count below 150,000,000/ml and/or absolute neutrophil count less then 1500/mm3
  • Alkaline phosphatase or AST greater than 5 times the upper limit of normal or ALT greater than 4 times the upper limit of normal
  • Female patients who are pregnant or lactating
  • Use of any investigational agent within the last 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01039636

Locations
United States, California
Children's Hospital of Oakland
Oakland, California, United States, 94609
United States, Massachusetts
Children's Hospital of Boston
Boston, Massachusetts, United States, 02115
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Australia
Royal Adelaide Hospital
Adelaide, Australia
Thailand
Siriraj Hospital, Mahidol University
Bangkok, Thailand, 10700
Sponsors and Collaborators
FerroKin BioSciences, Inc.
Investigators
Principal Investigator: Ellis Neufeld, MD Children's Hosptial of Boston
  More Information

No publications provided

Responsible Party: FerroKin BioSciences, Inc.
ClinicalTrials.gov Identifier: NCT01039636     History of Changes
Other Study ID Numbers: FBS0701-CTP-03
Study First Received: December 23, 2009
Last Updated: February 8, 2012
Health Authority: United States: Food and Drug Administration
Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by FerroKin BioSciences, Inc.:
Beta-thalassemia
Sickle cell anemia
Transfusional iron overload
Iron overload
Iron chelation

Additional relevant MeSH terms:
Beta-Thalassemia
Thalassemia
Iron Overload
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn
Iron Metabolism Disorders
Metabolic Diseases
Iron
Trace Elements
Micronutrients
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 31, 2014